RRC ID 47008
Author Melo NR, Taguchi H, Culhari VP, Kamei K, Mikami Y, Smith SN, Vilela MS.
Title Oral candidiasis of HIV-infected children undergoing sequential HIV therapies.
Journal Med Mycol
Abstract Candida oral flora from 52 Brazilian HIV-infected children was characterized while they received antiviral monotherapy therapy and subsequently, HAART with the use of protease inhibitor. There was a significant increase in non-C. albicans Candida isolates from 9.6-28.8% (P=0.005) after the children were placed on protease inhibitor therapy. Although Candida albicans still remained the most commonly isolated species, relative presence of C. tropicalis (n=9) followed by C. parapsilosis (n=8) markedly increased in association with protease inhibitor therapy. Furthermore, rare Candida species including C. dubliniensis, C. norvegensis, C. humicula and C. rugosa also appeared after the onset of protease inhibitor therapy. Subsequent investigation of the antifungal sensitivity of these diverse isolates, derived during protease inhibitor therapy, demonstrated some variation in antifungal sensitivity. With notable exceptions, the majority were sensitive to amphotericin B while most C. albicans and non-C. albicans Candida isolates were also susceptible to fluconazole, itraconazole and ketoconazole. Amongst exceptions was a single C. tropicalis isolates which was resistant to fluconazole (MIC>64 microl/ml) and one C. albicans-B isolate which showed cross-resistance to all azoles and amphotericin.
Volume 47(2)
Pages 149-56
Published 2009-3-1
DOI 10.1080/13693780802195315
PII 795276401
PMID 18651304
MeSH AIDS-Related Opportunistic Infections* / epidemiology AIDS-Related Opportunistic Infections* / microbiology Adolescent Amphotericin B / administration & dosage Amphotericin B / pharmacology Amphotericin B / therapeutic use Antifungal Agents / pharmacology Antiretroviral Therapy, Highly Active Azoles / administration & dosage Azoles / pharmacology Azoles / therapeutic use Brazil / epidemiology Candida* / classification Candida* / drug effects Candida* / isolation & purification Candidiasis, Oral / complications Candidiasis, Oral / epidemiology* Candidiasis, Oral / microbiology* Child Child, Preschool Drug Administration Schedule Drug Therapy, Combination Female HIV Infections* / complications HIV Infections* / drug therapy HIV Infections* / immunology HIV Infections* / virology HIV Protease Inhibitors / administration & dosage HIV Protease Inhibitors / therapeutic use Humans Male Microbial Sensitivity Tests Species Specificity
IF 2.822
Times Cited 10
Pathogenic microorganisms